Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.
about
Emerging drugs for uveitisA Clinical Picture of the Visual Outcome in Adamantiades-Behçet's DiseaseCurrent concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation.Proinflammatory cytokines and C-reactive protein in uveitis associated with Behçet's diseaseImmunopathogenesis of ocular Behçet's diseaseLong-term efficacy of infliximab on background vascular leakage in patients with Behçet's disease.The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patientsImmune mediated diseases and immune modulation in the neurocritical care unitOutcome measures used in clinical trials for Behçet syndrome: a systematic review.Cyclosporine-Associated Leukoencephalopathy in a Case of Sympathetic Ophthalmitis.Neuro-Behçet, pseudotumor cerebri and ocular signs: a rare associationEvidence-based practice in Behçet's disease: identifying areas of unmet need for 2014.Update on the therapy of Behçet disease.Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls.Tumor necrosis factor biologics beyond psoriasis in dermatology.Light on the horizont: biologicals in Behçet uveitis.The role of biologic agents in the management of non-infectious uveitis.Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis.TNF inhibition for ophthalmic indications: current status and outlook.Current and future treatments for Behçet's uveitis: road to remission.Approaches to immunosuppression in Behçet's disease.Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy.A Major Review: Current Aspects of Ocular Behçet's Disease in Japan.Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis.The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.Role of IL-22- and TNF-α-producing Th22 cells in uveitis patients with Behcet's diseaseInhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.Cystoid Macular Edema: Possible Complication of Infliximab Therapy in Behçet's Disease.[Behcet's disease--ophthalmological and general aspects: Part 2: Therapy].Psoriasis triggered by infliximab in a patient with Behçet's disease.Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study.[Biologics: from the "golden calf" to a "gold standard"?].[Anti-TNF-α treatment for uveitis. Analysis of the current situation].
P2860
Q24630848-FDDB3EA5-7FD9-4528-BBB6-230CD69DB4CCQ26777598-5A275A2F-011E-42A8-8C10-8E2F0BFC7257Q27693189-C4F6ABB0-332B-4BAC-99CC-5C80E97DBDB2Q33796694-7E8C9A2D-F770-4551-AE96-DB3E79330187Q33908937-A4B86719-6A44-4F45-A420-6D2319BE8E91Q34041295-2ED862F2-3C1D-44DC-8D79-9656818E1302Q34220221-BC84A4AF-34B5-4322-A9C6-75AD1F6797F4Q35699360-1C1A4E57-9200-4FC8-B862-6660458D01B1Q35729575-0A23BE3E-C948-4DCF-A89C-1941DE7A9BD9Q35868282-177B0F78-4CDC-4FB7-87E0-668EDE9EBFFEQ36635008-7C894B55-F127-4702-8294-44FECC7CD593Q37241274-02798683-9511-4F07-9EB2-38CD8315949DQ37539557-018C2780-6283-4DB6-B16B-48DE2BA13EF2Q37712230-29665206-7FA0-4E81-8066-60CDB00C7A51Q37810960-B5123EB7-308A-4480-A83F-8368FA1A9ACEQ37886194-D337F138-739A-4A5D-805C-7514F5D1C90DQ38004097-58E2BD61-7DB1-48EC-9E7D-8068955E7FDFQ38025152-26F1D3F4-FCEC-46A7-BACB-16680B444452Q38074446-E6C6E98E-A9EA-4200-B296-A9B05B887C47Q38097327-F648B768-6F03-459E-B503-CCB1514C0684Q38111308-F6F416B2-4815-4B16-A02D-73B01857DDB4Q38119551-B8E5E1F6-0480-4181-AF28-513243B6832EQ38152971-185FD9E6-C965-45EE-A472-712EAE5FEC46Q38545948-14EDBE29-D9D7-4C3F-B3AF-E712AE2C0CE7Q38773144-66E047AC-8A6F-450B-998E-16D485E84101Q38925320-E916E0BA-76EB-4FE7-B2E0-601F397BDD9AQ39158352-18C66EEC-6318-4BC7-84FB-FDA9CD0A4504Q41954592-F75E93A3-7EDD-4FD4-AAD0-055D1FF4C56AQ42592766-5B389650-BBA6-49F9-8B41-EA08E29E0596Q44524653-8404FB0B-DD89-40B3-B30B-67AF58D599FAQ44575051-7C0D6608-C034-4502-8859-B0C39C510714Q48368367-2BE0C6E8-B1FB-480B-B46E-B19D5B893AC5Q51371234-DD90A215-296F-47AF-AF69-ACA4E9E39A59Q52897654-DB79FF15-88C5-4CC8-8EF3-6211A0B9C137Q52899661-3614E81A-E17F-4FE6-8017-FD38E2B99CE2
P2860
Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparison of infliximab versu ...... ment period in Behçet disease.
@en
Comparison of infliximab versu ...... ment period in Behçet disease.
@nl
type
label
Comparison of infliximab versu ...... ment period in Behçet disease.
@en
Comparison of infliximab versu ...... ment period in Behçet disease.
@nl
prefLabel
Comparison of infliximab versu ...... ment period in Behçet disease.
@en
Comparison of infliximab versu ...... ment period in Behçet disease.
@nl
P2093
P356
P1476
Comparison of infliximab versu ...... ment period in Behçet disease.
@en
P2093
Hiroyuki Tanaka
Koju Kamoi
Manabu Mochizuki
Sunao Sugita
Tatsushi Kawaguchi
Yukiko Yamada
P304
P356
10.1136/BJO.2009.158840
P407
P577
2009-08-18T00:00:00Z